An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Clinical trial NCT02617589 · COMPLETED
Trial details
- NCT number
- NCT02617589
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-01
- Primary completion
- 2019-01-17
- Enrollment
- 560
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.